To better understand the patients’ response heterogeneity, we quantified nilotinib uptake by primary CP-CML cells in standardized conditions using flow cytometry, which allowed also distinguishing mature (polymorphonuclear cells) from immature (CD34+) cells. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.